543-KRAS抑制剂:肿瘤治疗新格局与耐药挑战 episode artwork

EPISODE · Feb 23, 2026 · 20 MIN

543-KRAS抑制剂:肿瘤治疗新格局与耐药挑战

from 聊聊Sci

这篇综述深入探讨了RAS基因家族(尤其是KRAS)在人类癌症中的致病机制及治疗进展。文章详细解释了RAS蛋白作为分子开关在细胞生长中的生理功能,以及突变如何导致其持续处于激活状态并引发肿瘤恶化。作者重点介绍了KRAS G12C抑制剂(如sotorasib和adagrasib)的突破性研发历程,并分析了当前临床面临的主要障碍——耐药性机制。此外,文中还评估了针对G12D、G12V等突变体的下一代异构体选择性抑制剂和泛RAS抑制剂的开发现状。最后,该文献强调了通过联合用药策略和早期干预来克服疗效局限性的未来方向。References: Emerging landscape of KRAS inhibitors in cancer treatmentRiedl, Jakob M. et al.Cancer Cell, Volume 0, Issue 0前往小宇宙评论区与主播互动

Episode metadata supplied by the publisher feed · Published Feb 23, 2026

Embed this episode

Ready to play

543-KRAS抑制剂:肿瘤治疗新格局与耐药挑战

0:00 20:31

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of 聊聊Sci?

This episode is 20 minutes long.

When was this 聊聊Sci episode published?

This episode was published on February 23, 2026.

Can I download this 聊聊Sci episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!